Ipsen Pharma: Ipsen presents strong full-year 2022 results and guidance for 2023
2022 total sales up by 8.5% at CER1 (14.4% as reported) with growth platforms'2 sales increasing by 20.9%1 and Somatuline® (lanreotide) sales declining by 5.6%12022 core operating margin of 36.9%, broadly